Inhibitors of BRAF dimers using an allosteric site
FDA-approved RAF inhibitors poorly inhibit BRAF dimers, which limits their clinical efficacy in tumors expressing BRAFV600E mutant monomers. Here the authors identify FDA-approved Ponatinib as an effective inhibitor of BRAF monomers and dimers and designed PHI1, an inhibitor with a unique mode of ac...
Guardado en:
Autores principales: | Xiomaris M. Cotto-Rios, Bogos Agianian, Nadege Gitego, Emmanouil Zacharioudakis, Orsi Giricz, Yang Wu, Yiyu Zou, Amit Verma, Poulikos I. Poulikakos, Evripidis Gavathiotis |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/164ffa3380c14391b97d067789d509e0 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Eltrombopag directly inhibits BAX and prevents cell death
por: Adam Z. Spitz, et al.
Publicado: (2021) -
Cutaneous sarcoidosis due to immune‐checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor
por: J. P. Pham, et al.
Publicado: (2021) -
Photosensing and Thermosensing by Phytochrome B Require Both Proximal and Distal Allosteric Features within the Dimeric Photoreceptor
por: E. Sethe Burgie, et al.
Publicado: (2017) -
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Hima Patel, et al.
Publicado: (2021) -
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
por: Maria Gonzalez-Cao, et al.
Publicado: (2021)